An investigation of the Scottish medicines consortium (SMC) impact on and engagement with stakeholders

M. Bennie, C. Black, V. Cairns, S. Hems, L. Mciver, J. Nicholson, S. Oduro, R. Payne, W. Ramsay

Research output: Contribution to journalConference Contribution

22 Citations (Scopus)

Abstract

A poster presentation on the Scottish medicines consortium. SMC advises NHS Scotland about the status of newly licensed medicines, new formulations of existing medicines and new indications for established products. An investigation was undertaken to identify how SMC has impacted on NHS board Area Drug and
Therapeutics Committees (ADTCs) in their assessment of new medicines, and the views of key stakeholders (ADTCs, public partners and pharmaceutical industry).

Fingerprint

Pharmacy and Therapeutics Committee
Posters
Drug Industry
Scotland
Medicine
Pharmaceutical Preparations

Keywords

  • medicine
  • Scotland
  • consortium
  • area drug and therapeutics committees
  • ADTCs

Cite this

Bennie, M. ; Black, C. ; Cairns, V. ; Hems, S. ; Mciver, L. ; Nicholson, J. ; Oduro, S. ; Payne, R. ; Ramsay, W. / An investigation of the Scottish medicines consortium (SMC) impact on and engagement with stakeholders. In: Basic and Clinical Pharmacology and Toxicology . 2009 ; Vol. 105, No. Supp.1. pp. 92-92.
@article{66ddf6eb5a784c48914d81bbdd7f9b0a,
title = "An investigation of the Scottish medicines consortium (SMC) impact on and engagement with stakeholders",
abstract = "A poster presentation on the Scottish medicines consortium. SMC advises NHS Scotland about the status of newly licensed medicines, new formulations of existing medicines and new indications for established products. An investigation was undertaken to identify how SMC has impacted on NHS board Area Drug andTherapeutics Committees (ADTCs) in their assessment of new medicines, and the views of key stakeholders (ADTCs, public partners and pharmaceutical industry).",
keywords = "medicine, Scotland, consortium, area drug and therapeutics committees, ADTCs",
author = "M. Bennie and C. Black and V. Cairns and S. Hems and L. Mciver and J. Nicholson and S. Oduro and R. Payne and W. Ramsay",
year = "2009",
month = "8",
doi = "10.1111/j.1742-7843.2009.00437.x",
language = "English",
volume = "105",
pages = "92--92",
journal = "Basic and Clinical Pharmacology and Toxicology",
issn = "1742-7835",
number = "Supp.1",

}

An investigation of the Scottish medicines consortium (SMC) impact on and engagement with stakeholders. / Bennie, M.; Black, C.; Cairns, V.; Hems, S.; Mciver, L.; Nicholson, J.; Oduro, S.; Payne, R.; Ramsay, W.

In: Basic and Clinical Pharmacology and Toxicology , Vol. 105, No. Supp.1, 08.2009, p. 92-92.

Research output: Contribution to journalConference Contribution

TY - JOUR

T1 - An investigation of the Scottish medicines consortium (SMC) impact on and engagement with stakeholders

AU - Bennie, M.

AU - Black, C.

AU - Cairns, V.

AU - Hems, S.

AU - Mciver, L.

AU - Nicholson, J.

AU - Oduro, S.

AU - Payne, R.

AU - Ramsay, W.

PY - 2009/8

Y1 - 2009/8

N2 - A poster presentation on the Scottish medicines consortium. SMC advises NHS Scotland about the status of newly licensed medicines, new formulations of existing medicines and new indications for established products. An investigation was undertaken to identify how SMC has impacted on NHS board Area Drug andTherapeutics Committees (ADTCs) in their assessment of new medicines, and the views of key stakeholders (ADTCs, public partners and pharmaceutical industry).

AB - A poster presentation on the Scottish medicines consortium. SMC advises NHS Scotland about the status of newly licensed medicines, new formulations of existing medicines and new indications for established products. An investigation was undertaken to identify how SMC has impacted on NHS board Area Drug andTherapeutics Committees (ADTCs) in their assessment of new medicines, and the views of key stakeholders (ADTCs, public partners and pharmaceutical industry).

KW - medicine

KW - Scotland

KW - consortium

KW - area drug and therapeutics committees

KW - ADTCs

U2 - 10.1111/j.1742-7843.2009.00437.x

DO - 10.1111/j.1742-7843.2009.00437.x

M3 - Conference Contribution

VL - 105

SP - 92

EP - 92

JO - Basic and Clinical Pharmacology and Toxicology

T2 - Basic and Clinical Pharmacology and Toxicology

JF - Basic and Clinical Pharmacology and Toxicology

SN - 1742-7835

IS - Supp.1

ER -